• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » PPD, SNBL form Japanese clinical development joint venture

PPD, SNBL form Japanese clinical development joint venture

January 5, 2015
CenterWatch Staff

Pharmaceutical Product Development (PPD), a global CRO based in Wilmington, N.C., and Japan-based Shin Nippon Biomedical Laboratories (SNBL) have formed a joint venture to provide a full range of clinical development services in Japan, including phase I-IV clinical trial monitoring, project management, site intelligence and activation, biostatistics, data management, medical writing, pharmacovigilance, regulatory and FSP services.

The joint venture, to be named PPD-SNBL, will result from the combination of SNBL’s clinical research division and PPD’s clinical development operations in Japan, and will have offices in Tokyo, Osaka and Kagoshima with approximately 400 clinical development professionals. This combination brings together PPD’s global clinical trial experience with SNBL’s nearly 20-year history of providing clinical development services for biopharmaceutical companies in Japan.

PPD-SNBL will be majority owned by PPD. Ryoichi Nagata M.D., Ph.D., chairman and president of SNBL, will be president of the joint venture.

The companies also have entered into an agreement to collaborate in a number of areas outside of the clinical development joint venture in Japan. This collaboration will involve SNBL’s early stage businesses (including translational research out-licensing business), phase I services in the U.S. for Japanese bridging studies, specialized neuroscience studies, vaccines studies and biologic studies, phase I services in Japan, Japanese bioanalysis services and site management services in Japan.

David Simmons, chairman and CEO of PPD, said, “PPD-SNBL will be one of the largest clinical development service providers in Japan, both for clients seeking to conduct global clinical trials and also for trials based solely in Japan, and builds on the shared commitment of both organizations to the delivery of high-quality clinical development services.”

The transactions are subject to customary closing conditions and are expected to close in April 2015.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing